Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 49 entries
Sorted by: Best Match Show Resources per page
Newer concepts in the therapy of pulmonary malignancies.

The Journal of the Medical Society of New Jersey

Koven BJ.
PMID: 5247998
J Med Soc N J. 1968 Dec;65(12):652-4.

No abstract available.

Cite
Koven BJ. Newer concepts in the therapy of pulmonary malignancies. J Med Soc N J. 1968;65(12):652-4
Koven, B. J. (1968). Newer concepts in the therapy of pulmonary malignancies. The Journal of the Medical Society of New Jersey, 65(12), 652-4.
Koven, B J. "Newer concepts in the therapy of pulmonary malignancies." The Journal of the Medical Society of New Jersey vol. 65,12 (1968): 652-4.
Koven BJ. Newer concepts in the therapy of pulmonary malignancies. J Med Soc N J. 1968 Dec;65(12):652-4. PMID: 5247998.
Copy Download .nbib Format: NLM
[Small-cell carcinoma of the lung. Recent data].

La Presse medicale

Israel L.
PMID: 5637803
Presse Med. 1968 Jan 06;76(1):17-20.

No abstract available.

Cite
Israel L. Les cancers à petites cellules du poumon. Données récentes. [Small-cell carcinoma of the lung. Recent data]. Presse Med. 1968;76(1):17-20
Israel, L. (1968). Les cancers à petites cellules du poumon. Données récentes. [Small-cell carcinoma of the lung. Recent data]. La Presse medicale, 76(1), 17-20.
Israel, L. "Les cancers à petites cellules du poumon. Données récentes." [Small-cell carcinoma of the lung. Recent data]. La Presse medicale vol. 76,1 (1968): 17-20.
Israel L. Les cancers à petites cellules du poumon. Données récentes. [Small-cell carcinoma of the lung. Recent data]. Presse Med. 1968 Jan 06;76(1):17-20. French. PMID: 5637803.
Copy Download .nbib Format: NLM
[Attitude of the physician to inoperable cancer of the lung].

La Revue du praticien

Decroix G.
PMID: 4131557
Rev Prat. 1973 Mar 01;23(13):1245-50.

No abstract available.

Cite
Decroix G. Attitude du médecin devant un cancer du poumon inopérable. [Attitude of the physician to inoperable cancer of the lung]. Rev Prat. 1973;23(13):1245-50
Decroix, G. (1973). Attitude du médecin devant un cancer du poumon inopérable. [Attitude of the physician to inoperable cancer of the lung]. La Revue du praticien, 23(13), 1245-50.
Decroix, G. "Attitude du médecin devant un cancer du poumon inopérable." [Attitude of the physician to inoperable cancer of the lung]. La Revue du praticien vol. 23,13 (1973): 1245-50.
Decroix G. Attitude du médecin devant un cancer du poumon inopérable. [Attitude of the physician to inoperable cancer of the lung]. Rev Prat. 1973 Mar 01;23(13):1245-50. French. PMID: 4131557.
Copy Download .nbib Format: NLM
[Challenge and up-to-date of molecule target therapy in lung cancer].

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases

Han BH.
PMID: 17445464
Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):83-5.

No abstract available.

Cite
Han BH. [Challenge and up-to-date of molecule target therapy in lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi. 2007;30(2):83-5
Han, B. H. (2007). [Challenge and up-to-date of molecule target therapy in lung cancer]. Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 30(2), 83-5.
Han, Bao-Hui. "[Challenge and up-to-date of molecule target therapy in lung cancer]." Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases vol. 30,2 (2007): 83-5.
Han BH. [Challenge and up-to-date of molecule target therapy in lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi. 2007 Feb;30(2):83-5. Chinese. PMID: 17445464.
Copy Download .nbib Format: NLM
Consolidation chemotherapy after chemoradiation? Not the right answer to not the right question?.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Curran WJ.
PMID: 23945381
J Thorac Oncol. 2013 Sep;8(9):1116-7. doi: 10.1097/JTO.0b013e3182a61949.

No abstract available.

Cite
Curran WJ. Consolidation chemotherapy after chemoradiation? Not the right answer to not the right question?. J Thorac Oncol. 2013;8(9):1116-7doi: 10.1097/JTO.0b013e3182a61949.
Curran, W. J. (2013). Consolidation chemotherapy after chemoradiation? Not the right answer to not the right question?. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 8(9), 1116-7. https://doi.org/10.1097/JTO.0b013e3182a61949
Curran, Walter J. "Consolidation chemotherapy after chemoradiation? Not the right answer to not the right question?." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 8,9 (2013): 1116-7. doi: https://doi.org/10.1097/JTO.0b013e3182a61949
Curran WJ. Consolidation chemotherapy after chemoradiation? Not the right answer to not the right question?. J Thorac Oncol. 2013 Sep;8(9):1116-7. doi: 10.1097/JTO.0b013e3182a61949. PMID: 23945381.
Copy Download .nbib Format: NLM
Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy".

Clinical lung cancer

Satoh H, Miyazaki K, Kagohashi K.
PMID: 33781693
Clin Lung Cancer. 2021 Sep;22(5):e782. doi: 10.1016/j.cllc.2021.02.016. Epub 2021 Feb 27.

No abstract available.

Cite
Satoh H, Miyazaki K, Kagohashi K. Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy". Clin Lung Cancer. 2021;22(5):e782doi: 10.1016/j.cllc.2021.02.016.
Satoh, H., Miyazaki, K., & Kagohashi, K. (2021). Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy". Clinical lung cancer, 22(5), e782. https://doi.org/10.1016/j.cllc.2021.02.016
Satoh, Hiroaki, et al. "Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy"." Clinical lung cancer vol. 22,5 (2021): e782. doi: https://doi.org/10.1016/j.cllc.2021.02.016
Satoh H, Miyazaki K, Kagohashi K. Letter to the Editor Regarding "Cutaneous Toxicities in Lung Cancer Patients on Immune Checkpoint Inhibitor Therapy". Clin Lung Cancer. 2021 Sep;22(5):e782. doi: 10.1016/j.cllc.2021.02.016. Epub 2021 Feb 27. PMID: 33781693.
Copy Download .nbib Format: NLM
Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis.

European journal of cancer (Oxford, England : 1990)

Duchemann B, Pluvy J, Crestani B, Zalcman G, Nunes H.
PMID: 33958266
Eur J Cancer. 2021 Jul;151:252-253. doi: 10.1016/j.ejca.2021.04.001. Epub 2021 May 04.

No abstract available.

Cite
Duchemann B, Pluvy J, Crestani B, et al. Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. Eur J Cancer. 2021;151:252-253doi: 10.1016/j.ejca.2021.04.001.
Duchemann, B., Pluvy, J., Crestani, B., Zalcman, G., & Nunes, H. (2021). Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. European journal of cancer (Oxford, England : 1990), 151252-253. https://doi.org/10.1016/j.ejca.2021.04.001
Duchemann, Boris, et al. "Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis." European journal of cancer (Oxford, England : 1990) vol. 151 (2021): 252-253. doi: https://doi.org/10.1016/j.ejca.2021.04.001
Duchemann B, Pluvy J, Crestani B, Zalcman G, Nunes H. Response to letter entitled: Re: Immune checkpoint blockade for patients with lung cancer and idiopathic pulmonary fibrosis. Eur J Cancer. 2021 Jul;151:252-253. doi: 10.1016/j.ejca.2021.04.001. Epub 2021 May 04. PMID: 33958266.
Copy Download .nbib Format: NLM
Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

de Souza Gutierres B, Aguiar PN, Dourado BB, Alves AL, Matsas S, Simões AR, Del Giglio A.
PMID: 32217131
J Thorac Oncol. 2020 Jul;15(7):1170-1176. doi: 10.1016/j.jtho.2020.03.004. Epub 2020 Mar 23.

INTRODUCTION: Clinical trials are expensive and often require funding from the pharmaceutical industry (PI). We aimed to compare studies funded by the PI with those funded by other sources in terms of costs, reported results, and strength of evidence.METHODS:...

Cite
de Souza Gutierres B, Aguiar PN, Dourado BB, et al. Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding. J Thorac Oncol. 2020;15(7):1170-1176doi: 10.1016/j.jtho.2020.03.004.
de Souza Gutierres, B., Aguiar, P. N., Dourado, B. B., Alves, A. L., Matsas, S., Simões, A. R., & Del Giglio, A. (2020). Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15(7), 1170-1176. https://doi.org/10.1016/j.jtho.2020.03.004
de Souza Gutierres, Barbara, et al. "Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 15,7 (2020): 1170-1176. doi: https://doi.org/10.1016/j.jtho.2020.03.004
de Souza Gutierres B, Aguiar PN, Dourado BB, Alves AL, Matsas S, Simões AR, Del Giglio A. Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding. J Thorac Oncol. 2020 Jul;15(7):1170-1176. doi: 10.1016/j.jtho.2020.03.004. Epub 2020 Mar 23. PMID: 32217131.
Copy Download .nbib Format: NLM
Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior.

Nano letters

Dong Z, Yan S, Liu B, Hao Y, Lin L, Chang T, Sun H, Wang Y, Li H, Wu H, Hang X, He S, Hu J, Xue X, Wu N, Chang L.
PMID: 33830766
Nano Lett. 2021 Jun 09;21(11):4878-4886. doi: 10.1021/acs.nanolett.1c00199. Epub 2021 Apr 08.

The genetic heterogeneities in cancer cells pose challenges to achieving precise drug treatment in a widely applicable manner. Most single-cell gene analysis methods rely on cell lysis for gene extraction and identification, showing limited capacity to provide the correlation...

Cite
Dong Z, Yan S, Liu B, et al. Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior. Nano Lett. 2021;21(11):4878-4886doi: 10.1021/acs.nanolett.1c00199.
Dong, Z., Yan, S., Liu, B., Hao, Y., Lin, L., Chang, T., Sun, H., Wang, Y., Li, H., Wu, H., Hang, X., He, S., Hu, J., Xue, X., Wu, N., & Chang, L. (2021). Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior. Nano letters, 21(11), 4878-4886. https://doi.org/10.1021/acs.nanolett.1c00199
Dong, Zaizai, et al. "Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior." Nano letters vol. 21,11 (2021): 4878-4886. doi: https://doi.org/10.1021/acs.nanolett.1c00199
Dong Z, Yan S, Liu B, Hao Y, Lin L, Chang T, Sun H, Wang Y, Li H, Wu H, Hang X, He S, Hu J, Xue X, Wu N, Chang L. Single Living Cell Analysis Nanoplatform for High-Throughput Interrogation of Gene Mutation and Cellular Behavior. Nano Lett. 2021 Jun 09;21(11):4878-4886. doi: 10.1021/acs.nanolett.1c00199. Epub 2021 Apr 08. PMID: 33830766.
Copy Download .nbib Format: NLM
Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Wang Z, Jia Q, Tang X, Yan L, Zhu B.
PMID: 31864552
J Thorac Oncol. 2020 Jan;15(1):e1-e3. doi: 10.1016/j.jtho.2019.07.035.

No abstract available.

Cite
Wang Z, Jia Q, Tang X, et al. Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC. J Thorac Oncol. 2020;15(1):e1-e3doi: 10.1016/j.jtho.2019.07.035.
Wang, Z., Jia, Q., Tang, X., Yan, L., & Zhu, B. (2020). Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 15(1), e1-e3. https://doi.org/10.1016/j.jtho.2019.07.035
Wang, Zhongyu, et al. "Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC." Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer vol. 15,1 (2020): e1-e3. doi: https://doi.org/10.1016/j.jtho.2019.07.035
Wang Z, Jia Q, Tang X, Yan L, Zhu B. Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC. J Thorac Oncol. 2020 Jan;15(1):e1-e3. doi: 10.1016/j.jtho.2019.07.035. PMID: 31864552.
Copy Download .nbib Format: NLM
Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report.

Journal of immunotherapy (Hagerstown, Md. : 1997)

Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, Sohal R, Leibovitch J, Basnet A.
PMID: 31261166
J Immunother. 2019 Nov/Dec;42(9):348-349. doi: 10.1097/CJI.0000000000000285.

Immunotherapies such as the cytotoxic T-lymphocyte-associated protein 4 inhibitor ipilimumab and the programmed cell death protein 1 inhibitor nivolumab have become ubiquitous in cancer treatment. Recently, the FDA approved nivolumab with or without ipilimumab for the treatment of refractory...

Cite
Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, et al. Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. J Immunother. 2019;42(9):348-349doi: 10.1097/CJI.0000000000000285.
Pomerantz, M., Lichtenstein, D. A., Niesvizky-Kogan, I., Sohal, R., Leibovitch, J., & Basnet, A. (2019). Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. Journal of immunotherapy (Hagerstown, Md. : 1997), 42(9), 348-349. https://doi.org/10.1097/CJI.0000000000000285
Pomerantz, Madison, et al. "Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report." Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 42,9 (2019): 348-349. doi: https://doi.org/10.1097/CJI.0000000000000285
Pomerantz M, Lichtenstein DA, Niesvizky-Kogan I, Sohal R, Leibovitch J, Basnet A. Nivolumab and Ipilimumab-induced Acute Inflammatory Demyelinating Polyradiculoneuropathy: A Case Report. J Immunother. 2019 Nov/Dec;42(9):348-349. doi: 10.1097/CJI.0000000000000285. PMID: 31261166.
Copy Download .nbib Format: NLM
The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours.

Acta oncologica (Stockholm, Sweden)

Haik L, Gonthier A, Quivy A, Gross-Goupil M, Veillon R, Frison E, Ravaud A, Domblides C, Daste A.
PMID: 34549686
Acta Oncol. 2021 Dec;60(12):1597-1603. doi: 10.1080/0284186X.2021.1978540. Epub 2021 Sep 22.

BACKGROUND: Evidence suggests that sarcopenia is a significant predictive factor of worst outcomes and treatment-associated toxicities in patients with metastatic solid tumours. The aim of this study was to explore the relationship between low muscle mass and clinical outcomes...

Cite
Haik L, Gonthier A, Quivy A, et al. The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta Oncol. 2021;60(12):1597-1603doi: 10.1080/0284186X.2021.1978540.
Haik, L., Gonthier, A., Quivy, A., Gross-Goupil, M., Veillon, R., Frison, E., Ravaud, A., Domblides, C., & Daste, A. (2021). The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta oncologica (Stockholm, Sweden), 60(12), 1597-1603. https://doi.org/10.1080/0284186X.2021.1978540
Haik, Laura, et al. "The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours." Acta oncologica (Stockholm, Sweden) vol. 60,12 (2021): 1597-1603. doi: https://doi.org/10.1080/0284186X.2021.1978540
Haik L, Gonthier A, Quivy A, Gross-Goupil M, Veillon R, Frison E, Ravaud A, Domblides C, Daste A. The impact of sarcopenia on the efficacy and safety of immune checkpoint inhibitors in patients with solid tumours. Acta Oncol. 2021 Dec;60(12):1597-1603. doi: 10.1080/0284186X.2021.1978540. Epub 2021 Sep 22. PMID: 34549686.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 49 entries